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Abstract
Background: Pulmonary hypertension (PH) represents an important complication of idiopathic pulmonary fibrosis (IPF) with
a negative impact on patient survival. Herpes viruses are thought to play an etiological role in the development and/or
progression of IPF. The influence of viruses on PH associated with IPF is unknown. We aimed to investigate the influence of
viruses in IPF patients focusing on aspects related to PH. A laboratory mouse model of gamma-herpesvirus (MHV-68)
induced pulmonary fibrosis was also assessed.
Methods: Lung tissue samples from 55 IPF patients and 41 controls were studied by molecular analysis to detect various
viral genomes. Viral molecular data obtained were correlated with mean pulmonary arterial pressure (mPAP) and arterial
remodelling. Different clinical and morphological variables were studied by univariate and multivariate analyses at time of
transplant and in the early post-transplant period. The same lung tissue analyses were performed in MHV-68 infected mice.
Results: A higher frequency of virus positive cases was found in IPF patients than in controls (p = 0.0003) and only herpes
virus genomes were detected. Viral cases showed higher mPAP (p= 0.01), poorer performance in the six minute walking test
(6MWT; p = 0.002) and higher frequency of primary graft (PGD) dysfunction after lung transplant (p = 0.02). Increased arterial
thickening, particularly of the intimal layer (p= 0.002 and p = 0.004) and higher TGF-b expression (p= 0.002) were
demonstrated in viral cases. The remodelled vessels showed increased vessel cell proliferation (Ki-67 positive cells) in the
proximity to metaplastic epithelial cells and macrophages. Viral infection was associated with higher mPAP (p= 0.03), poorer
performance in the 6MWT (p = 0.008) and PGD (p= 0.02) after adjusting for other covariates/intermediate factors. In MHV-68
infected mice, morphological features were similar to those of patients.
Conclusion: Herpesviral infections may contribute to the development of PH in IPF patients.
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Introduction
Idiopathic pulmonary fibrosis (IPF), morphologically usual
interstitial pneumonia, is a chronic progressive disease of unknown
aetiology with irreversible scarring in the lung [1]. No proven
effective treatment is available other than lung transplantation.
Survival time is estimated at 2.5 years after initial diagnosis,
although disease progression is highly variable [2,3]. Acute
exacerbation, lung cancer and pulmonary hypertension (PH) are
the main complications which adversely affect the survival of IPF
patients. Different from acute exacerbation which can occur at any
stage of the disease, lung cancer and pulmonary hypertension (PH)
are more likely in advanced disease. For the latter, a frequency of
20–90% has been reported and it carries severe consequences
including decreased exercise capacity and increased mortality
before and after lung transplantation [4–7].
Recent studies have shown that PH measured with right-heart
catheterization or transthoracic echocardiography in IPF patients
is associated with low DLCO, shorter walk distances, and
desaturation during exercise [5,6]. Similar relationships have been
identified when brain natriuretic peptide was used as a surrogate
marker for PH in IPF patients [8].
However to date no clinical or biohumoral parameters are
available as predictive markers of PH in IPF patients. Several
authors have shown that PH in IPF relates poorly to the degree of
pulmonary function test and is not always confined to advanced
disease [6]. Indeed even in end stage IPF cohorts, no association
between the presence of PH and severity of the disease (both in
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terms of functional parameters and fibrosis extension) has been
observed [6,9].
Pathogenic mechanisms of IPF and of its main complications
are complex and still largely unknown although different
hypotheses have been proposed, varying from previous chronic
inflammation with subsequent widespread fibrosis to abnormal
wound healing. Increasing evidence suggests that a key event in
IPF is deregulated epithelial cell function with ongoing alveolar
epithelial injury and an associated abnormal host repair response,
leading to patchy and heterogeneous morphological changes [10].
The complex biological processes that underlie pulmonary fibrosis
might directly contribute to the pathogenesis of vascular remodel-
ling which is equally patchy and heterogeneous. Fibrotic areas
have fewer blood vessels but adjacent, non fibrotic tissues seem
highly vascularised [11]. Structural changes range from capillary
loss to complex vascular lesions with intima, media thickening and
adventitial fibrosis. Endothelial injury, usually occurring through
apoptotic cell death is another crucial aspect in the pathogenesis of
IPF-associated PH as reported in recent studies [12–14]. Different
types of mediators, including those released by injured endothelial
cells, may be involved in vascular remodelling by influencing vessel
smooth muscle or adventitial cell proliferation. Several studies
have implicated viral infection as a cause of epithelial injury and
therefore an important factor in its pathogenesis [15–34]. Among
viral agents herpes viruses, in particular Epstein Barr virus (EBV),
have been suggested as principal cofactors (as initiating or
exacerbating agents) of fibrotic lung disease and treatment with
ganciclovir has been shown to attenuate disease progression in
a subgroup of patients [35].
Alveolar epithelial cells, one of the most important targets of the
virus, are then involved in the activation of different signalling
pathways responsible for fibrotic lung remodelling. In viral animal
and cell models several profibrogenic cytokines/chemokines have
been shown to be over-expressed and among these transforming
growth factor beta 1 (TGF-b1) plays a key role [27,32–34]. While
many works, experimental and clinical, have highlighted the
influence of EBV in promoting fibrotic parenchymal remodelling,
its influence on endothelial injury and vessel remodelling and
other related parameters of PH has not been yet assessed.
The aim of the study was to investigate the relevance of
respiratory viruses in IPF patients, with special emphasis on cases
complicated by PH. For this purpose a large number of IPF
patients and control subjects including other non-IPF diffuse
parenchymal lung diseases (DPLDs) were studied. Viral molecular
data were correlated with mean pulmonary arterial pressure
(mPAP) and arterial remodelling. Different clinical and morpho-
logical variables were studied by univariate and multivariate
analysis at time of transplant and in the early post-transplant
period.
A mouse model was used to examine whether murine
gammaherpesvirus-68 (MHV-68), genetically and biologically
similar to EBV, contributes to the development of vessel
remodelling other than pulmonary fibrosis.
Materials and Methods
Study Population
Native lungs from 55 IPF patients who underwent lung
transplantation (LT) between September 1998 and February
2010 in our Centre were studied (39 males and 16 females; mean
age: 55.269.2 yrs, 33 single vs 22 bilateral LT). The control group
consisted of 22 native lungs from other non-IPF -DPLDs- (8 males
and 14 females; mean age: 44611.4 yrs, 11 lymphangioleiomyo-
matosis, 4 Langerhans-cell histiocytosis, 2 sarcoidosis, 2 hypersen-
sitivity pneumonitis, 1 non-specific interstitial pneumonia, 1
desquamative interstitial pneumonia, 1 scleroderma lung fibrosis)
and 19 normal lungs (13 non implanted donor lungs and 6 autopsy
cases). Prior to LT after the diagnosis of IPF, the majority received
oral prednisone while a minority were treated with prednisone and
azathioprine.
Each patient underwent pulmonary function testing, high
resolution computed tomography and right heart catheterization.
These tests were performed in all patients at the time of waiting list
inclusion and before LT. For the present study clinical/functional
parameters collected at the time of LT were considered.
The diagnosis of interstitial lung disease was based on the
diagnostic criteria of the American Thoracic Society/European
Respiratory Society Consensus Classification System [1]. The
clinical history was collected, with special emphasis on age at onset
of symptoms, smoking history, occupational exposure, co-morbid-
ities and therapy (medical and non medical).
Moreover, short term post-transplant follow-up (12 months after
LT) was also considered in all IPF cases, mainly focusing on
primary graft dysfunction (PGD) and acute rejection, both
considered causes of early and late graft dysfunction. PGD and
acute rejection were graded as proposed by the International
Society for Heart and Lung Transplantation (ISHLT) Working
Group [36,37]. Acute rejection was evaluated in 143 scheduled
transbronchial biopsies collected in the first post-transplant year.
These data have been presented at the 2010 ISHLT annual
meeting.
Written informed consent was obtained from all subjects. The
work was approved by the Institutional Ethics Committee.
Relevant clinical data of the IPF and non-IPF DPLD population
are summarized in Table 1.
Table 1. Study subjects (IPF patients and non-IPF DPLDs).
IPF patients (n =55) DPLDs (n =22)
Age at transplantation (years) 55.1 (7.9) 44.1 (12.6)
Type of transplantation (bilateral) 22 (40.0%) 16 (72.7%)
Men 39 (70.9%) 9 (40.2%)
BMI 27.1 (4.0) 23.4 (5.2)
Smoking status
never smoked 9 (16.4%) 10 (45.4%)
previous smoker 46 (83.6%) 7 (31.8%)
History of environmental exposure 3 (5.5%) 0
Co-morbidities
Gastritis 5 (9.1%) 1 (4.5%)
Diabetes 6 (10.9%) 0
CHD 4 (7.3%) 0
Obesity 13 (23.6%) 2 (9.1%)
FEV1 (% of predicted value) 47.9 (16.2) 39.2 (25.3)
FVC (% of predicted value) 45.6 (14.5) 49.0 (22.4)
VC (% of predicted value) 43.4 (14.3) 51.0 (21.0)
TLC (% of predicted value) 53.4 (15.4) 71.4 (20.9)
DLco (% of predicted value) 26.0 (17.0) 23.5 (20.5)
mPAP 24.0 (8.9) 28.8 (15.4)
Data are number of patients (%) or mean (sd). IPF: idiopathic pulmonary fibrosis;
DPLDs: Diffuse parenchymal lung diseases; BMI: body mass index; CHD:
coronary heart disease.
doi:10.1371/journal.pone.0055715.t001
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Molecular Viral Detection
Nucleic acids were extracted from fresh lung tissues sampled
from different areas (,1 mg of tissue) of all 96 cases (55 IPF
patients and 41 control subjects) using a modified RNAzol method
[38]. Reverse transcriptase (RT)-polymerase chain reaction (PCR),
PCR or nested-PCR were used to detect principal respiratory viral
genomes: adenovirus, cytomegalovirus (CMV), EBV, rhinovirus,
influenzavirus A and B, metapneumovirus, herpes virus (HHV)-6,
HHV-7, HHV-8, parvovirus (PV) B19, parainfluenzavirus 1 and 3
and respiratory syncytial virus (as heminested PCR) as previously
reported [39]. The oligonucleotides used to ascertain the quality of
extracted RNA or DNA were complementary to the mRNA
glyceraldehyde-3-phosphate dehydrogenize (3GPDH) and b-glo-
bin gene, respectively [40,41,]. All samples were processed
alongside negative controls (i.e. reaction mixture without DNA
or RNA template) and positive (virally infected cells). Precautions
were taken to avoid false positive results due to contamination by
PCR product carry over, by strictly following guidelines for the
general handling of the PCR procedure, such as separation of
rooms, boards, and lab benches [42]. Sensitivity of PCR in our
laboratory has beforehand been reported [43].
Samples were considered as true positive when the reproduc-
ibility of PCR analysis was verified a second time. Amplicon
specificity was verified by direct cycle sequencing as previously
described [39].
Since EBV was identified with high frequency in IPF patients,
RNA-in situ hybridization-ISH (Epstein-Barr encoded RNAs,
Biogenex, San Ramon, CA) was performed to identify the viral
target cells. To quantify DNA viral genome copies real time PCR
was also carried out in EBV positive cases whose additional DNA
was available using artusH EBV TM PCR KIT [44].
Analysis of Fibrosis Extension, TGF-b Expression and
Vessel Remodelling
The extent of fibrosis was evaluated in Masson’s trichrome
stained sections analyzing 10 random fields using computer-
assisted morphometric software (Image ProPlusH 5.1), as pre-
viously reported [45]. The immunohistochemical detection and
quantification of the profibrotic cytokine TGF-b (mouse mono-
clonal anti-TGF-b NovoCastra, Newcastle, UK), was performed
as described before: immunostaining scores were based on the
products of percentage positive cells multiplied by stain intensity
(0 = negative, 1 = weak, 2 = moderate, 3 = strong) in three different
high power fields. Control sections were stained without the
primary antibody, without primary and secondary antibodies, or
with normal sera to control for background reactivity [45].
Arterial thickening was quantified using computer-assisted
morphometric software on elastic-Van Gieson (EVG) stained lung
sections focusing on muscular arteries of an average diameter of
300 mm (range: 100–500 mm). In particular, medial thickening
(MT) was evaluated as previously described in at least 5 arterial
sections. The same approach was used to measure intimal
thickening (IT): MT% = (2 6 medial layer thickening/external
diameter) 6 100; IT% = (2 6 intimal layer thickening/external
diameter)6100 [46]. The assessment of vascular remodelling also
included an evaluation of apoptosis and proliferation of vessel cell
components using the TUNEL technique and Ki-67 immunos-
taining respectively, as previously described [47]. Briefly, for
TUNEL, after proteinase K (Boehringer, Mannheim, Germany)
digestion at a concentration of 20 mg/ml, the slides were
incubated with TdT/biotinylated dUTP diluted in buffer
(Boehringer, Mannheim, Germany) and any labeling visualized
with 3-39-diaminobenzidine and 30 ml hydrogen peroxide. Slides
incubated in buffer without TdT or biotinylated UTP served as
negative controls and slides incubated with 1 mg/ml DNAse
(Sigma-Aldrich, Milan, Italy) served as positive controls.
For Ki-67 immunohistochemistry, after microwave antigen
retrieval, the sections were treated with normal serum (Immuno-
tech, Marseille, France) and incubated for 60 min with the
primary monoclonal antibody anti-Ki67 (MIB-1, Gene Tex,
Irvine, CA) at a dilution of 1:100. Sections were subsequently
incubated with rabbit HRP polymer (Dako, Glostrup, Denmark)
for 30 min. Immunoreactivity was visualized with 3-39-diamino-
benzidine (Dako). Negative controls processed omitting the
primary antibody did not show any reaction. Ki-67 expression
and TUNEL positivity were evaluated only in blood vessel cell
components. All evaluations were performed blindly.
Animal Model
Female, 5 to 8 week old CD-1 mice [Hsd:ICR (CD1)] were
purchased from Harlan Laboratories, UK and housed at the
University of Liverpool under specific pathogen-free conditions.
Mice were intranasally infected with 46105 PFU MHV-68 and
euthanized 7 days (n = 3), 14 days (n = 6) and 23 days (n = 3) post
infection (post infection). Uninfected mice (n = 4) served as
controls.
Immediately after death, lungs were collected and parts frozen
at 280uC for RNA extraction: others were fixed in 10% buffered
formalin and routinely embedded in paraffin wax. All experiments
were performed in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of The
National Institutes of Health. The protocol was approved by UK
Home Office regulations and under Project Licence number 40/
2483 and Personal Licence number 60/6501. All infections were
performed under light isoflorane anaesthesia. All experiments were
carried out in manner to minimize suffering.
Analysis of Fibrosis Extension, TGF-b Expression and
Vessel Remodelling
Consecutive paraffin-embedded sections were stained with
haematoxylin and eosin for histology, with Masson’s trichrome
stain for fibrosis extension and with EVG for vessel remodelling,
both morphometrically measured as above. The evaluation of
arterial thickening focused on pulmonary arteries with an average
diameter of 82 mm ranging from 43 to 100 mm. The assessment of
vascular remodelling also included an evaluation of apoptosis and
proliferation of vessel cell components using the TUNEL
technique and Ki-67 immunostaining, as described above. Ki-67
antibody used for this analysis was rabbit polyclonal (Abcam,
Cambridge, UK). Immunohistochemistry was also employed for
the detection of MHV-68 antigen, to highlight lung macrophages
(expression of lysozyme) and to demonstrate TGF-b expression
(Genetex, Irvane, CA). Viral tRNA was demonstrated by RNA-
ISH [48].
Statistical Analysis
Data were analyzed using the SAS statistical software version
9.1.3 (SAS Institute, Cary, NC, USA). For quantitative variables
the results are expressed as mean values 6 standard deviation if
normally distributed, otherwise as median, Q1–Q3. The normality
of distribution of quantitative variables was tested by means of
Shapiro-Wilk statistics. For quantitative characteristics, differences
between subjects with and without viral infection were evaluated
by using the Mann-Whitney test. The prevalence of specific
conditions was expressed as a percentage, and differences between
groups were evaluated using the x-squared test and exact Fisher’s
test, as adequate.
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Unadjusted and adjusted relationships between virus and
clinical/morphological features were tested with general linear
models (GLM procedure). In all analyses, a two-tail level for
significance was set at 0.05. Simple logistic regression models were
applied to estimate odds ratios (ORs) for PGD using recipients’
and donors’ characteristics as predictors. A multivariate logistic
model was used to estimate the adjusted OR of virus for PGD,
controlling for PAP.25 mmHg. Considering that incidence was
quite common in the study population, adjusted risk ratios (RRs)
were approximated from adjusted ORs [49].
Results
Study Population
Viral data, tissue and vessel remodelling. Patients with
IPF showed a higher frequency of viral infection than control cases
(40% vs 7.3%; p = 0.0003). Normal lungs were all negative. Herpes
viruses were the only detected genomes in IPF and EBV resulted
as the most frequent, present in more than half of IPF patients. In
2 cases double infection was found. EBV was never detected in
control cases (DPLDs and normal lungs). Gene sequencing of all
amplicons showed a high homology (from 95% to 99%) with
human viral genome sequences. RNA-ISH for EBV (EBER)
identified viral RNA in 40% of EBV-PCR positive IPF cases. The
positivity was detected in alveolar epithelial cells other than within
monocytes/macrophages (Figure 1). Real time PCR showed a high
number of EBV genome copies (mean6SD:10850006120208
copies/ml DNA). The extent of fibrosis in IPF lungs showed a mean
of 36.7612.3% (range: 14.6%–65.3%) and was significantly
higher than in the DPLD control group (36.7612.3% vs
15.4615.4%, p,0.0001). Normal lungs from donors showed no
evidence of pathological remodelling.
TGF-b expression in IPF lungs was mainly detected in
macrophages (median, Q1–Q3: 100, 20–210) and metaplastic
alveolar epithelial cells (120, 70–210). Median TGF-b scores in the
alveolar epithelium were significantly higher in IPF patients than
in the DPLD group (120, 70–210 vs 0, 0–0, p,0.0001). In normal
lungs, TGF-b expression was restricted to only scattered
intraalveolar macrophages. Arterial remodelling in IPF cases
showed a median total thickness score of 43.8% (Q1–Q3: 35.7–
53.1%) with IT and MT scores of 17.7% (Q1–Q3: 13.5–24%) and
26.2% (Q1–Q3: 21.8–28.9%) respectively. These values were
significantly lower in the DPLD group (total thickness: 37.9% vs
43.8%, p = 0.03; IT: 12.3% vs 17.7%, p = 0.005). Normal lungs did
not show arterial remodelling (Table 2).
Correlation between viral molecular data and clinical/
morphological parameters in IPF patients. Virus-positive
IPF cases showed increased mPAP (28.6610.9 mmHg vs
21.266.0 mmHg, p = 0.01) and worse performance in the
6MWT (175.26100 vs 300.56138.8, p = 0.002) than virus
negative cases (Figure 2 A,B). The statistical value of these
associations (mPAP and 6MWT) was still evident when EBV
positive IPF patients were compared with both other virus positive
and negative IPF cases (p,0.05 for both).
Virus positive IPF cases showed a higher total thickening of
muscular arteries (50.3%, 43.8–58.8% vs 39.5%, 34.7–45.7%,
p = 0.002) than virus negative cases. The intimal layer was most
severely affected (21.8%, 17.2–26.8% vs 15.5%, 12.6–19.1%;
p = 0.004) (Figure 3 A,B,C,D). TUNEL staining was mainly
detected in the endothelial cells of the microvasculature (Figure
S1) while cell proliferation was frequently seen in remodelled
pulmonary arteries. Strong Ki-67 positivity was observed in
both endothelial cells (CD31 positive, data not shown) and
smooth muscle cells (smooth muscle actin positive, data not
shown). Vessel cell proliferation was particularly seen in
pulmonary arteries in proximity to metaplastic alveolar epithelial
cells or macrophages (Figure 4 A and B). TGF-b scores were
Figure 1. In situ hybridization for EBV. EBER transcripts well seen in the nuclei of two alveolar epithelial cells (arrows). Bar scale: 10 mm.
doi:10.1371/journal.pone.0055715.g001
Herpes Virus and Vascular Remodeling in IPF
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e55715
higher in virus-positive cases, although this was only statistically
significant when epithelial expression was considered (score: 195,
140–210 vs 100, 40–120; p = 0.002) (Figure 5 A,B,C,D). The
statistical value of these parameters (vessel remodelling and
TGF-b expression) was still evident when EBV positive IPF
patients were compared with both other virus positive and
negative IPF cases (p,0.05 for all). A summary of all main
clinicopathological features in relation to virus infection among
IPF patients is shown in the Table S1.
Viral presence was significantly associated with higher mPAP
(p = 0.03) after adjusting for other related covariates and in-
termediate factors (i.e.; age, sex, duration of disease, smoking
history, and fibrosis extension). Moreover, viral presence was an
independent marker of significantly poorer performance in the
6MWT (p = 0.008) using the GLM adjusting for covariates (i.e.
VC, FVC, DLCO and fibrosis extension). When we considered
the short-term post-transplant follow-up we found a higher
frequency of PGD (50% vs 14%, p= 0.02) and, although not
statistically significant, an increased rate of acute rejection (50% vs
25%, p: ns) in virus positive compared to negative IPF cases. A
multivariate analysis identified an increased risk for PGD to be
associated with viral infection independently of the major re-
cipient/donor characteristics that are usually considered to
influence PGD, including PH (adjusted RR: 5.43, 95% CI:
1.56–7.10, p= 0.02) (Table S2).
MHV-68 Infected CD1 Mice
Tissue and vessel remodelling. Analysis of MHV-68 DNA
load showed, as previously demonstrated, that viral infection
peaked on day 7 post infection [50].
The histological examination of uninfected control animals
did not identify any pathological changes. On day 7 post
infection, all infected animals exhibited increased, macrophage-
dominated interstitial cellularity, mild type II pneumocyte
hyperplasia and perivascular inflammatory infiltration. The
latter infiltrates were associated with slight patchy collagen
Table 2. Viral genome frequency and pathological data in IPF and control cases.
IPF patients (55) Control cases (41)* p-values
Virus positive cases 22/55 (40%) 3/41 (7.3%) 0.0003
EBV 13/22 (59.1%) 0
HHV-6 7/22 (31.8%) 1/3 (33.3%)**
CMV 4/22 (18.2%) 2/3 (66.7%)**
PVB19 0 1/3 (33.3%)**
Fibrotic extension, mean % (SD) 36.7 (12.3) 15.4 (15.4)*** ,0.0001
Medial arterial remodelling, median % (Q1–Q3) 26.2 (21.8–28.9) 22.4 (18.9–27.5)*** ns
Intimal arterial remodelling, median % (Q1–Q3) 17.7 (13.5–24.0) 12.3 (9.0–17.0) *** 0.005
Total arterial remodelling, median % (Q1–Q3) 43.8 (35.7–53.1) 37.9 (31.7–44.6) *** 0.03
Macrophagic TGF-ß score, median % (Q1–Q3) 100 (20–210) 50 (10–180) *** ns
Alveolar epithelial TGF-b score, median % (Q1–Q3) 120 (70–210) 0 (0–0)*** ,0.0001
IPF: idiopathic pulmonary fibrosis; EBV: Epstein Barr virus; HHV6: herpes virus 6; CMV: cytomegalovirus PV: parvovirus; TGF : transforming growth factor.
*All donor lungs were negative;
**these viruses were detected only in patients with LAM.
Double infections were detected in two IPF patients and 1 control case.
***These parameters were quantified only in DPLD patients, not in normal lungs.
doi:10.1371/journal.pone.0055715.t002
Figure 2. Mean pulmonary arterial pressure (mPAP) values. Significant higher values of mPAP (A) and worse 6MWT (B) in virus positive
compared to virus negative cases.
doi:10.1371/journal.pone.0055715.g002
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Figure 3. Vascular remodelling in IPF lung tissue. Significantly increased arterial thickening (A) particularly of the intimal layer (B) is seen in
virus positive cases. Elastic Van Gieson stained sections showed increased wall thickening (increased elastic and collagen fibers) especially of the
intimal layer (arrow) in virus positive (C) compared to virus negative cases (D). Bar scale: 100 mm. L = lumen.
doi:10.1371/journal.pone.0055715.g003
Figure 4. Vessel cell proliferation in IPF lung tissue. Strong Ki-67 immunostaining was observed both in endothelial (A, arrows) and in smooth
muscle cells (B, arrows) of remodelled pulmonary arteries adjacent to metaplastic epithelial cells (well seen in A, arrowhead). Bar scale: 10 mm.
doi:10.1371/journal.pone.0055715.g004
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deposition. Scattered individual macrophages and metaplastic
alveolar epithelial cells were found to express MHV-68 antigen.
Viral latency, represented by the expression of viral tRNA, was
detected in type II pneumocytes and alveolar macrophages. On
day 14 post infection, mild multifocal, almost diffuse fibrosis of
alveolar septa was observed with a median of 26% (range: 17–
38%). In some animals, this was associated with random
patches of collagen deposition. Numerous macrophages were
seen within the interstitium and often around arteries. In
addition, some type II pneumocytes exhibited TGF-b expression
(Figure 6 A, B).
Arteries were assessed for vessel remodelling and compared for
the thickening scores. In uninfected control mice, the average
score was 16.5. Seven and 14 days post infection, it was 18 and
24.5 respectively (Figure 7 A,B,C,D). The extent of fibrosis was
slightly more marked in mice with vessel wall thickening. On day
23 post infection both the parenchymal and vessel remodelling
were less evident. Similar to human cases TUNEL staining was
mainly detected in endothelial cells of the microvasculature (Figure
S2) while cell proliferation was frequently seen in endothelial cells
and smooth muscle cells of pulmonary arteries, in particular in
vessels surrounded by macrophages (Figure 8 A, B).
Discussion
In the present study different respiratory viruses were in-
vestigated in lungs from a large cohort of IPF patients and the
control group (non IPF DPLDs and normal lungs) displaying the
prevalent role of herpes viruses. The work highlights the broad
impact of herpesviral infection, particularly EBV, in the disease
emphasizing its association with a more severe disease phenotype
as IPF with associated higher mPAP and worse 6MWT. A
multiple logistic regression analysis demonstrated that herpesviral
infection was independently associated with more marked vessel
remodelling, higher value of PAP and worse performance in the
6MWT.Neither clinical data (smoking history, age at diagnosis
and at transplant, duration of the disease, BMI, lung volumes and
hypoxemic respiratory failure) nor morphological changes (fibrosis
extension) had more significant impact than viral infection. Of
particular note is that the presence of viral infection had also early-
term negative influence on the graft function. IPF virus positive
recipients showed a higher frequency of PGD, independent of
other recipient and donor characteristics. Viral products and/or
the activated immune system related to viral infection in native
IPF lungs may potentiate the immune response to alloantigens
after transplantation, thus resulting in early graft dysfunction.
Only one previous study performed on 24 IPF patients reported
Figure 5. TGF-b expression in IPF lung tissue. A) Significantly increased TGF-b median score values of epithelial cells are seen in virus positive
cases. B) TGF-b median score values of macrophages in virus positive and virus negative cases. Stronger and more extensive TGF-b immunostaining
well seen in virus positive (C) than virus negative case (D). Bar scale: 5 mm.
doi:10.1371/journal.pone.0055715.g005
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Figure 6. Immunohistochemistry for TGF-b in lung tissue of MHV-68 infected CD1 mice. Numerous metaplastic alveolar epithelial cells
(arrows) are marked (A); positive macrophages (arrows) are seen around a remodelled artery (B). Bar scale: 40 mm.
doi:10.1371/journal.pone.0055715.g006
Figure 7. Vascular remodelling in lung tissue of MHV-68 infected CD1mice. Haematoxylin-Eosin (A, C) and Masson’ trichrome (B, D) stained
sections: marked arterial thickening is seen in a MHV-68 infected mouse (A and B, scale bars: 20 mm) in comparison to an uninfected mouse (C and D).
Bar scale: 20 mm. A: small artery; V: venule.
doi:10.1371/journal.pone.0055715.g007
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more rapid disease progression in EBV positive cases. The
majority of viral cases died from respiratory failure at a mean of
41 month follow up. In the study PH was not specifically
considered [51].
The reported frequency of herpes viruses in IPF lungs ranges
from 30 to 100%. These differences may be related to technical
sensitivity, disease heterogeneity or selection of patients. The
presence of herpes viruses detected in our cases may even be
underestimated due the fact that the molecular investigation was
performed on tissue samples from end-stage diseases. Viral
clearance, after initial injury, could occur in some cases with
persistence and progression of lung injury due to activation of an
immunological response, as it occurs in other chronic virus-related
diseases, e.g. dilated-cardiomyopathy-post-myocarditis [52]. EBV,
the most frequent herpes virus detected in IPF, has a well known
epitheliotropism other than lymphotropism. Several works have
detected EBV in alveolar epithelial cells of IPF lungs, thus
confirming the concept that these cells represent the principal viral
target in IPF [15,27,29,30,33,53]. The role of herpes viruses,
important contributing factors for the development of pulmonary
fibrosis, has been emphasized in different experimental models
and the TGF–b signalling pathway seems to play a crucial role in
the profibrogenetic action.
To the best of our knowledge no attempt has been made to
specifically investigate the influence of herpes viruses on arterial
remodelling and PH in IPF patients.
Several types of viruses, particularly those of the herpes family,
have been found to be associated with vessel remodelling,
development of atherosclerosis and clinical features of hyperten-
sion [54,55]. Vasculotropism of gamma herpes viruses (such as
HHV-8, EHV-5 and MHV68) has been demonstrated in lung
parenchyma of patients and animals (horses) with PH even if
a causal relationship still remains quite debated [55–57]. Up to
today, there is little evidence of a ‘‘direct’’ role of viral agents in the
pathogenesis of PH. Even when more significant arterial intimal
thickness could more convincingly suggest a direct viral endothe-
lial injury, in our work EBV was never detected in endothelial cells
of IPF cases. The presence of chemokines and cytokines, viral
protein components, and increased expression of growth and
transcriptional factors released at the site of infection could
contribute to further recruitment of inflammatory cells and
proliferation of smooth muscle and endothelial cells. An interesting
finding of our study was the most frequent distribution of
remodelled vessels with proliferating components in proximity to
metaplastic epithelial cells and/or macrophages, both cell types
considered as principal targets of EBV. Injured epithelial or
endothelial cells involved in tissue and vessel remodelling are
considered an important source of growth factors and mediators,
among which TGF-b plays a key role.
Although the function of TGF in vascular cell growth in vivo has
not been well defined, in vitro and experimental studies have
demonstrated an important influence of this cytokine in muscle/
fibroblast proliferation, endothelial-mesenchymal transition, and
extracellular matrix production of intimal and medial layers [58].
In our study significantly higher TGF-b levels detected in our viral
IPF cases as well as in MHV-68 infected mice suggest an indirect
influence of viral infection on vessel remodelling through this
cytokine even if TGF-b expression was not significantly related to
arterial thickening. Similar data were found by Farkas L. et al. in
a different experimental model of pulmonary fibrosis [13]. The
authors detected high levels of active TGF-b in areas with
increased fibrogenesis and pulmonary artery remodelling. At day
14, this was significantly associated with pulmonary hypertension.
The demonstration of a direct causal relationship between
herpesvirus infection and vessel remodelling/PH in IPF would
require longitudinal studies of the same patients, an impossible
task with lung tissue but attainable with bronchoalveolar lavage or
peripheral blood samples. However this limitation has been
partially overcome in the present study using a laboratory MHV-
68 infected mouse model. Indeed, in these animals 2 weeks after
infection significant arterial remodelling and increased TGF-
b expression was seen, as those observed in clinical lung specimens
from IPF patients with high mPAP.
Conclusion
In summary, our results demonstrated for the first time
a different phenotype of virus-positive IPF patients. In particular
virus-positive IPF cases showed more pronounced vessel remodel-
Figure 8. Vessel cell proliferation in lung tissue of MHV-68 infected CD1mice. Strong Ki-67 immunostaining was observed both in
endothelial (A, arrow) and smooth muscle (B, arrows) cells adjacent to macrophages. Bar scale: 20 mm.
doi:10.1371/journal.pone.0055715.g008
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ling and a higher mPAP and significantly higher PGD after
transplantation. While there is large mechanistic evidence of
epithelial herpesvirus-associated alveolar injury, the effect of these
viruses on the pulmonary vasculature in IPF merits investigation.
A deeper knowledge of viral-induced pathways in endothelial cells
could give new insights for a targeted therapeutic approach of this
important complication in the subgroup of patients (virus positive
cases). In this context, the high degree of similarity between MHV-
68 infection of CD-1 mice and virus positive IPF indicates that this
is an excellent model with which to study pathogenesis and
interventions.
Supporting Information
Figure S1 Cell apoptosis in IPF lung tissue. Endothelial
cell apoptosis (TUNEL positive) well seen in a capillary
surrounded by extensive fibrosis (arrows). Bar scale: 10 mm.
(TIF)
Figure S2 Cell apoptosis in MHV-68 infected CD1 mice
lungs. Endothelial cell apoptosis (TUNEL positive, arrow) well
seen in a capillary of high remodeled area. Note apoptotic body
inside a macrophage (arrow head). Bar scale: 10 mm.
(TIF)
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